SCHEMBL16013124

SCHEMBL16013124

CCCCCCCCCC(=O)OCCCCCCCCOS(C)(=O)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.65
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
NAAA Q02083 1/20 0.55
DNM1 Q05193 1/20 0.54
HTR2C P28335 1/20 0.53
PAM P19021 2/20 0.50
TSHR P16473 2/20 0.50
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.50
USP2 O75604 1/20 0.50
MMP9 P14780 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPT P10636 1/20 0.47
RAD52 P43351 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
FAAH O00519 1/20 0.46
CA1 P00915 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16013011 1.00 DGKA (0.65) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL16023755 0.97 DGKA (0.59) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL8811522 0.88 LMNA (0.52) DGKANAAADNM1TSHRALDH1A1
SCHEMBL1533557 0.86 ALDH1A1 (0.54) DGKADNM1PAMTSHRALDH1A1
SCHEMBL25243121 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL23042055 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL25245209 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL23041629 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL23041315 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA
SCHEMBL25245190 0.86 DGKA (0.87) DGKAPRSS1PRSS2PRSS3NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3188760-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2023-12-06 EP disclosed
CN-107072946-B Lipids and lipid compositions for delivery of active agents 诺华股份有限公司 2022-01-11 CN disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
US-10844002-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-11-24 US disclosed
US-10844002-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-11-24 US disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 US disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 US disclosed
EP-3608308-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2020-02-12 EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 EP disclosed
US-20190002393-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2019-01-03 US disclosed
US-20170275243-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2017-09-28 US disclosed
US-20170275243-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2017-09-28 US disclosed
EP-3188760-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2017-07-12 EP disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
WO-2016037053-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2016-03-10 WO disclosed
WO-2016037053-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2016-03-10 WO disclosed
EP-2964608-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2016-01-13 EP disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844002-B2 Lipids and lipid compositions for the delivery of active agents LRAT, LIPA, LPAR1 DGKA 1107/4885PRSS1 3604/4885PRSS2 3705/4885
US-20170275243-A1 Lipids and Lipid Compositions for the Delivery of Active Agents LRAT, LPAR4, LPAR1 DGKA 1100/4885PRSS1 3673/4885PRSS2 3777/4885
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 DGKA 1543/4885PRSS1 1513/4885PRSS2 2276/4885
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 DGKA 1543/4885PRSS1 1513/4885PRSS2 2276/4885
US-20190002393-A1 Lipids and Lipid Compositions for the Delivery of Active Agents LRAT, LIPA, LPAR1 DGKA 1107/4885PRSS1 3604/4885PRSS2 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.